Price T Rowe Associates Inc Novavax Inc Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Novavax Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 72,556 shares of NVAX stock, worth $867,044. This represents 0.0% of its overall portfolio holdings.
Number of Shares
72,556
Previous 56,065
29.41%
Holding current value
$867,044
Previous $269,000
241.64%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding NVAX
# of Institutions
284Shares Held
83.2MCall Options Held
5.43MPut Options Held
9M-
Vanguard Group Inc Valley Forge, PA14.1MShares$168 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.8MShares$142 Million0.0% of portfolio
-
Shah Capital Management9.66MShares$115 Million41.87% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY6.32MShares$75.5 Million0.08% of portfolio
-
State Street Corp Boston, MA6.07MShares$72.5 Million0.0% of portfolio
About NOVAVAX INC
- Ticker NVAX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,215,104
- Market Cap $935M
- Description
- Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...